Compugen Ltd (NASDAQ: CGEN)

Compugen Ltd., also known as CGEN, operates in the field of therapeutic discovery and development, with a particular focus on cancer immunotherapy. The company's main business activities involve the discovery and development of novel drug targets and therapeutic products, leveraging its proprietary computational predictive capabilities. Compugen's operations are primarily based in the immuno-oncology field, and it generates revenue through the licensing of its intellectual property and the development of its therapeutic products.

Compugen's revenue generation is primarily driven by its primary products, which include COM701, a therapeutic antibody targeting PVRIG, and COM902, a therapeutic antibody targeting TIGIT. COM701 is a potentially first-in-class humanized antibody that binds with high affinity to PVRIG, a novel immune checkpoint target candidate discovered by Compugen. Blockade of PVRIG by COM701 has demonstrated potent, reproducible enhancement of T cell activation, consistent with the desired mechanism of action of activating T cells in the tumor microenvironment to generate anti-tumor immune responses. COM902, on the other hand, is a high-affinity, fully human antibody that targets TIGIT, an immune checkpoint. Preclinical studies have shown that TIGIT inhibition, either alone or in combination with other checkpoint inhibitors, can enhance T cell activation and increase anti-tumor immune responses.

Compugen's customer base includes pharmaceutical companies such as Bristol Myers Squibb and AstraZeneca, with whom it has collaborated on the development of its therapeutic products. These collaborations have provided Compugen with access to additional resources and expertise, enabling it to advance its therapeutic programs more quickly. The company's position within the industry is unique due to its proprietary computational predictive capabilities, which enable it to identify novel immune checkpoints and develop therapeutic antibodies that target these checkpoints. This capability sets Compugen apart from its competitors and provides it with a competitive advantage in the industry.

Compugen's therapeutic products have shown promising results in clinical trials. For instance, COM701 has demonstrated potent, reproducible enhancement of T cell activation in preclinical studies. Compugen has initiated several clinical trials to evaluate the safety and efficacy of COM701 in combination with other checkpoint inhibitors. The company has completed the enrollment of patients in its Phase 1 clinical trial of COM701 in combination with Opdivo (nivolumab) and Bristol Myers Squibb's investigational anti-TIGIT antibody, BMS-986207. The trial evaluated the safety, tolerability, and antitumor activity of the combination in patients with advanced solid tumors. Similarly, Compugen has initiated a Phase 1 clinical trial of COM902 in patients with advanced malignancies and has completed the enrollment of patients in its Phase 1 combination trial of COM902 with COM701.

In addition to COM701 and COM902, Compugen has licensed the development of Rilvegostomig, a novel PD-1/TIGIT bi-specific antibody with a TIGIT component derived from Compugen's COM902, to AstraZeneca. AstraZeneca is currently evaluating it in Phase 2 trials in patients with non-small cell lung cancer and gastric cancer. Compugen has also licensed the development of bapotulimab, a therapeutic antibody targeting ILDR2, to Bayer. Bayer is currently evaluating it in Phase 1 clinical trials in patients with head and neck squamous cell carcinoma.